GlassScriptPhysician profile
Donald J Mahon
NPI 1255335659
$19,260.52
in general payments reported to CMS, 2019-2025
54 companies · $3,947 in 2025
The $3,947 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,076 · 2020: $772 · 2021: $1,902 · 2022: $3,461 · 2023: $2,060 · 2024: $3,043 · 2025: $3,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,028 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,028.29 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,262.06 | 2019-2025 | Cardiomems, Pressurewire, Mitraclip |
| Novartis Pharmaceuticals Corporation | $2,232.13 | 2019-2025 | |
| Amgen INC. | $1,700.55 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $1,054.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $963.82 | 2021-2025 | Winrevair, Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $864.30 | 2019-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $851.12 | 2019-2025 | Uptravi, Opsumit |
| Aop Health US, LLC | $793.14 | 2025 | Rapiblyk |
| Sanofi-Aventis U.S. LLC | $767.36 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $725.80 | 2019-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $694.17 | 2022-2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $657.15 | 2019-2025 | Jardiance |
| Abiomed | $595.68 | 2023-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $520.90 | 2019-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $406.04 | 2022-2025 | Optimizer, Optimizer |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Mahon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.